EUCTR2005-003401-87-FR进行中（未招募）1 期
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 mg/day) or Extended Release Venlafaxine XR (150 mg/day to 225 mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1.Male or female outpatients aged 18-64 years, inclusive.
- •2.Subject currently meets the diagnosis for MDE associated with MDD, single episode or recurrent, according to DSM-IV-TR (296.2/296.3), diagnosed through a comprehensive psychiatric evaluation (in conjunction with the Mini International Neuropsychiatric Interview (MINI), Clinician Rated Version 5.0 [Sheehan, 1998]), as assessed by a physician with adequate training in psychiatry (e.g., Board Certification in psychiatry in US; Certificate of Completion of Specialist training in psychiatry in EU).
- •* Assessment by a physician with adequate training in psychiatry must include a face-to-face evaluation of the subject, but may be aided by subject evaluation conducted by a healthcare professional with a clinically relevant qualification (e.g., psychiatric nurse or psychologist) and a minimum of two years of documented experience assessing patients with MDD.
- •3.Subject must, in the investigator’s opinion based on clinical history, have met DSM-IV-TR (Appendix 6) criteria for their current MDE for at least 12 weeks but no greater than 24 months.
- •4.Subjects with an IVRS IDS-SR (Appendix 12) total score ?40 at the Screening and Randomization Visits.
- •5.Subjects must have a CGI-S (Appendix 11) score of ?4 at the Randomization Visit.
- •6.Subject must have the ability to comprehend the key components of the consent form and provide informed consent.
- •7.Subject must read and write at a level sufficient to complete study-related assessments.
- •8.A female subject is eligible to enter and participate in the study if she is of:
- •a.Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchal or post-menopausal)
- •Post-menopausal females defined as being amenorrhoeic for greater than two years with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). However, if indicated, this should be confirmed by estradiol and FSH levels consistent with menopause (according to local laboratory ranges).
- •Women who have not been confirmed as post-menopausal should be advised to use contraception as outlined below.
- •Pre-menopausal females with a documented (medical report verification) hysterectomy and/or bilateral oophorectomy only when reproductive status has been confirmed by hormone level assessment.
- •b.Child-bearing potential, has a negative pregnancy test at Screening and randomization, and agrees to satisfy one of the following requirements:
- •Complete abstinence from intercourse from commencement of last normal menstrual period (2 weeks minimum) prior to administration of the first dose of study drug, throughout the Treatment Phase, and for a minimum of 8 weeks after completion or premature discontinuation from the study drug; or,
- •Established use of acceptable methods of contraception from commencement of last normal menstrual period (3 weeks minimum) prior to administration of the first dose of study medication, throughout the Treatment Phase, and for a minimum of 8 weeks after completion or premature discontinuation from the study drug. Acceptable methods
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1.Subject’s IVRS IDS-SR (Appendix 12) assessment increases or decreases by more than 25% between the Screening (Week -1) and Randomization (Week 0) visits .
- •2.Subject has:
- •a.Symptoms of the presenting illness which are better accounted for by another diagnosis*; or
- •b.A current DSM-IV-TR diagnosis of Panic Disorder; or
- •c.Symptoms of generalized anxiety or panic attacks that in the investigator’s judgement could interfere with their ability to complete the trial; or
- •d.A current DSM-IV-TR diagnosis of Antisocial or Borderline Personality Disorder, Dementia, or another current DSM-IV-TR Axis II diagnosis that would suggest nonresponsiveness to pharmacotherapy or non-compliance with the protocol; or
- •e.A current (or within six months prior to the Screening visit) diagnosis of anorexia nervosa or bulimia; or
- •f.A DSM-IV-TR diagnosis of Bipolar Disorder, Schizophrenia, or other psychotic disorder(s).
- •*Major depressive disorder should be the condition that precipitates the evaluation (principal diagnosis) and the condition that best accounts for the clinical presentation (primary diagnosis). Secondary diagnoses of other anxiety disorders such as generalized anxiety disorder, posttraumatic stress disorder, social anxiety disorder, acute stress disorder, and obsessive-compulsive disorder are permissible.
- •3.Subject has an unstable medical disorder; or a disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GSK372475 or venlafaxine XR or may pose a safety concern, or interfere with the accurate assessment of safety or efficacy.
- •4.Subject has no contact with an adult on a daily basis (i.e., subjects who are not living with at least one other adult or subjects who do not have an adult who contacts them on a daily basis). This criterion only applies to sites in Canada, Mexico, Central and South America.
- •5.Patients under specific law protection in France named curatelle or tutelle (Guardianship) This criterion applies only to sites in France.
- •6.Subject has initiated psychotherapy within three months prior to the Screening (Week –1) visit, or plans to initiate psychotherapy during the trial. Subjects who present with their current MDD diagnosis despite longer-term psychotherapy (i.e. greater than three months prior to the Screening visit) may be included.
- •7.Subject has received electroconvulsive therapy or transcranial magnetic stimulation within the six months prior to the Screening (Week –1) visit.
- •8.Subject has previously failed an adequate therapeutic course of pharmacotherapy for MDD (e.g., for >4 weeks) from two different classes of antidepressants or two antidepressants within the same class.
- •9.Subject has a positive urine test at the Screening (Week –1) or Randomization (Week 0) visits for illicit drug use; a history of DSM diagnosed alcohol or substance abuse or dependence (other than nicotine) within the past 2 years or a blood alcohol level of >15mg/dl (0.015 %) at the Screening visit (Week –1). Note – subjects must be told to avoid consumption of alcoholic beverages for at least eight hours prior to their Screening visit. The
研究者
相似试验
进行中（未招募）
不适用
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder.Major depressive disorderMedDRA version: 8.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2005-003400-11-DEGlaxoSmithKline Research and Development Ltd492
进行中（未招募）
不适用
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 mg/day) or Extended Release Venlafaxine XR (150 mg/day to 225 mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder.MedDRA version: 8.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive DisorderEUCTR2005-003401-87-FIGlaxoSmithKline Research & Development399
进行中（未招募）
不适用
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 mg/day) or Extended Release Venlafaxine XR (150 mg/day to 225 mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder.Major Depressive DisorderEUCTR2005-003401-87-EEGlaxoSmithKline Research & Development399
进行中（未招募）
1 期
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 mg/day) or Extended Release Venlafaxine XR (150 mg/day to 225 mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder.MedDRA version: 8.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive DisorderEUCTR2005-003401-87-SKGlaxoSmithKline Research & Development399
进行中（未招募）
不适用
A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder - NDmajor depressive disorderMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionEUCTR2005-003400-11-ITGlaxoSmithKline Research Development Ltd492